ONGLYZA® (saxagliptin)

How do you choose the right DPP-4 inhibitor for your patients with type 2 diabetes?

Onglyza in the real world: No increased risk of hospitalisation for heart failure relative to sitagliptin

Hospitalisation for heart failure hazard ratios for Onglyza relative to sitagliptin1,2

Onglyza in the real world
Onglyza in the real world

An observational cohort study from a US claims database showed that there was no statistically significant difference in the hazards of hospitalisation for heart failure between Onglyza-versus sitagliptin-treated patients.

1. Fu AZ et al. Diabetes Care 2016; 39: 726-734.
2. Fu AZ et al. Risk of hopitalization for heart failure with dipeptidyl peptidase-4 inhibitors vs. sulfonylureas and with saxagliptin vs. sitagliptin in a U.S. claims database. Presented at the American Diabetes Association 75th Scientific Sessions, Boston, MA, 5-9 June 2015.